Short answer
10x Genomics, Inc. (TXG) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $151M (up 1.1% year over year) with net income of −$19M.
Q3 2026 key financials · XBRL
- Revenue
- $151M
- +1.1% YoY · −0.2% QoQ
- Net income
- −$19M
- +29.3% YoY · −8.3% QoQ
- Operating margin
- -10.7%
- Gross margin
- 75.0%
- EPS (diluted)
- −$0.15
- +31.8% YoY · −7.1% QoQ
Source: XBRL data from the 10x Genomics, Inc. (TXG) Q3 2026 10-Q on SEC EDGAR. USD.
10x Genomics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $150.7M, up $1.7M YoY, or 1%
- Gross margin 75% vs 67% YoY, driven by lower inventory write-downs and product mix
- Best segment: Single Cell consumables $93.1M, up $0.6M; worst: Spatial instruments $3.1M, down $4.0M
- Cash and securities $575.7M, up $52.3M from December 31, 2025; nine-month operating cash flow $58.9M vs $95.3M
- Outlook: fourth-quarter gross margin expected lower due to product mix; operating losses expected for the foreseeable future
Risk Factors
- Newly added risk, AI Technologies: 2026 Sentira launch and third-party foundation-model dependencies introduced validation, data security and regulatory uncertainties
- Most materially updated risk, Atera transition: shipments began September 2026, with Xenium and Visium revenue declines and expected margin pressure from instrument-heavy sales
- Regulatory risk, clinical expansion: CLIA certification and California licensure required before patient testing, with inspections and validation potentially delaying launch
- Market risk, research funding: NIH terminated approximately 700 grants totaling more than $2.4 billion in March 2025, pressuring customer purchases
- Financial risk, currency exposure: approximately 27% of sales denominated in non-U.S. currencies, without a current hedging program
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other 10x Genomics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.